ArticleFrontiers in genome editing2025
Construction of EpCAM overexpression and knockdown vectors and their implications in colorectal cancer research.
Article in Frontiers in genome editing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The functional characterization of Epithelial Cell Adhesion Molecule (EpCAM) in colorectal cancer (CRC) progression has been constrained by methodological limitations, particularly the potential for truncated protein isoforms to confound traditional genetic knockout approaches. This study aimed to develop a novel CRISPR/Cas9 strategy to overcome this challenge and systematically elucidate the context-dependent oncogenic roles of EpCAM across diverse CRC models. Methods: We engineered EpCAM overexpression (pCDH-EpCAM) and CRISPR/Cas9 knockdown (pGMC-KO-EpCAM) vectors using restriction digestion and T4 DNA ligation. A strategic dual-exon targeting approach (exons 1 and 3) was employed to minimize the risk of functional escape variants. Selected CRC cell lines (HT-29, HT-115, HRT-18) were genetically modified using optimized Lipofectamine 2000 transfection. Functional impacts were quantitatively assessed through: (i) flow cytometry for EpCAM surface expression (CD326-PE); (ii) daily cell counting over 8 days for proliferation kinetics; and (iii) scratch wound healing (0/24/48 h) and Transwell migration assays (8-μm pores, 18 h) to evaluate metastatic potential. Results: Successful genetic modulation was achieved and validated: HT-29-OE-EpCAM-2 exhibited an 89% EpCAM-positive rate versus 12% in wild-type (WT) (*p*<0.001), while HRT-18-KD-EpCAM-3 showed a significant reduction to 4% EpCAM-positive cells (vs. 15% in WT, *p*<0.001). EpCAM overexpression accelerated proliferation, with HT-29-OE cells showing a 20.1% increase in peak density on day 5 (30.76 ± 0.15 × 10 Conclusion: This study establishes a robust dual-vector toolkit for reliable EpCAM manipulation, highlighting a novel exon-targeting strategy that mitigates the limitations of previous approaches. Our findings demonstrate that EpCAM is a master regulator of CRC aggressiveness, dictating proliferative and metastatic phenotypes in a cell context-dependent manner. The genetically defined models provide a validated platform for therapeutic screening and safety assessment, forming a foundational resource for advancing EpCAM-targeted therapies and diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.